Panel recommends Serdolect for some schizophrenics

In an 8-2 vote, an expert panel recommended that Lundbeck's schizophrenia drug Serdolect be approved for some patients who struggle to control their disease. However, the panel did not support additional regulatory claim related to treatment of suicidal behaviour in schizophrenia. Release